Author

K. Weidele

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

C. Werno· 2 shared S. Treitschke· 2 shared A. Grujovic· 1 shared A. Kulik· 1 shared B. Polzer· 1 shared C. A. Klein· 1 shared C. Botteron· 1 shared C. Irlbeck· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Werno

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Lysosomal acid lipase-activity as a novel target to efficiently address triple-negative breast cancer high malignancy

H. Steigerwald, T. Bozzetti, M. Tams, J. On, G. Hoffmann, J. Lambertz, K. Weidele, S. Treitschke, F. Reinhardt, A. Kulik, N. Krawczyk, D. Niederacher, H. Neubauer, C. Werno, T. Rau, , K. Esser

This study shows that inhibiting lysosomal acid lipase (LIPA) reduces breast cancer stemness and sensitizes triple-negative breast cancer (TNBC) cells to chemotherapy, suggesting LIPA as a novel therapeutic target.

bioRxiv · Oct 1, 2023 · PreprintCancer Biology

Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during periods of clinical latency

M. Werner-Klein, A. Grujovic, C. Irlbeck, M. Obradovic, M. Hoffmann, H. Koerkel-Qu, X. Lu, S. Treitschke, C. Koestler, C. Botteron, K. Weidele, C. Werno, B. Polzer, S. Kirsch, M. Guzvic, , C. A. Klein

The paper identifies IL6 trans-signaling as a mechanism supporting DCC survival and outgrowth during clinical latency, with microenvironmental dependencies and PIK3CA mutations linked to metastatic progression.

bioRxiv · May 28, 2020Cancer Biology